US2012316126A1PendingUtilityA1
Compounds for the Treatment of Hepatitis C
Est. expirySep 11, 2028(~2.2 yrs left)· nominal 20-yr term from priority
Inventors:Kap-Sun YeungKyle E. ParcellaJohn A. BenderBrett R. BenoKatharine A. Grant-YoungYing HanPiyasena HewawasamJohn F. KadowAndrew Nickel
A61K 31/506C07D 405/10C07D 413/10C07D 491/10A61P 31/14C07D 407/12C07D 405/04C07D 453/00A61K 45/06C07D 417/10A61P 31/12C07D 409/12C07D 417/12C07D 405/12C07D 413/12C07D 307/84
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
Claims
exact text as granted — not AI-modified1 . A composition comprising the compound 4-Fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide or a pharmaceutically acceptable salt thereof, and at least one compound having anti-HCV activity effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH, and a nucleoside analog for the treatment of an HCV infection.
Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.